title: Smooth muscle cell migration promoting activity of plasma predicts restenosis in patients with peripheral arterial occlusive disease undergoing angioplasty.
abstract: BACKGROUND
  Efficacy of percutaneous transluminal angioplasty (PTA) is limited by restenosis occurring in a large proportion of patients. Smooth muscle cell (SMC) migration is a major pathomechanism of restenosis. We studied SMC migration inducing activity of plasma from patients with peripheral arterial occlusive disease (PAOD) undergoing PTA.
  
  
  RESULTS
  SMC migration was determined in a two-dimensional assay system after addition of 1/25 plasma dilutions. Mean increase in migration area was 65.5 +/- 33.8% in normal controls and 67.7 +/- 53.2% in patients with PAOD. 6 hours after PTA, plasmatic migration inducing activity was largely unchanged. In 19/30 patients with restenosis (6 months after PTA) migration promoting activity (82.7 +/- 60.0) was significantly higher than in 11/30 patients with patent vessels (41.8 +/- 21.0; p = 0.03). No correlation of clinical risk factors with outcome was observed. A weak correlation was found between plasmatic migration promoting activity and levels of epidermal growth factor and transforming growth factor-beta.
  
  
  CONCLUSIONS
  The capacity of human plasma to stimulate SMC migration in tissue culture can be used to assess the risk for restenosis after PTA in patients with PAOD.
authors.affiliation: Department of Vascular Biology, University of Vienna, Austria.
authors.forename: R E
authors.initials: RE
authors.lastname: Roller
authors.forename: S
authors.initials: S
authors.lastname: Janisch
authors.forename: E
authors.initials: E
authors.lastname: Kvas
authors.forename: W J
authors.initials: WJ
authors.lastname: Schnedl
authors.forename: B R
authors.initials: BR
authors.lastname: Binder
authors.forename: J
authors.initials: J
authors.lastname: Wojta
authors.forename: C
authors.initials: C
authors.lastname: Korninger
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D000800:Angioplasty, Balloon / Q000009:adverse effects; D001157:Arterial Occlusive Diseases / Q000378:metabolism* / Q000473:pathology; D016022:Case-Control Studies; D002465:Cell Movement / Q000187:drug effects; D046508:Culture Techniques; D005260:Female; D006083:Graft Occlusion, Vascular / Q000209:etiology*; D006133:Growth Substances / Q000097:blood / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000473:pathology*; D016491:Peripheral Vascular Diseases / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D010949:Plasma / Q000737:chemistry*; D016896:Treatment Outcome; D014469:Umbilical Arteries / Q000166:cytology / Q000187:drug effects
chemical_list: D006133:Growth Substances